Benchmark Lowers Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $15.00

Unicycive Therapeutics (NASDAQ:UNCY) had its target price cut by investment analysts at Benchmark from $21.00 to $15.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “speculative buy” rating on the stock. Benchmark’s price objective points to a potential upside of 124.55% from the company’s previous close.

Several other research analysts have also commented on the stock. Guggenheim lowered their price objective on shares of Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. Finally, Westpark Capital assumed coverage on shares of Unicycive Therapeutics in a research note on Thursday, February 19th. They issued a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Unicycive Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.67.

Unicycive Therapeutics Stock Performance

NASDAQ UNCY opened at $6.68 on Monday. The firm has a 50 day simple moving average of $6.65 and a 200-day simple moving average of $5.87. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $11.00. The firm has a market cap of $168.60 million, a price-to-earnings ratio of -3.08 and a beta of 1.81.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.36). Equities analysts predict that Unicycive Therapeutics will post -0.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vivo Capital LLC raised its holdings in Unicycive Therapeutics by 57.4% during the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock worth $7,804,000 after purchasing an additional 652,901 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Unicycive Therapeutics during the 4th quarter worth approximately $5,856,000. Vanguard Group Inc. lifted its position in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after buying an additional 52,925 shares during the last quarter. Cantor Fitzgerald L. P. purchased a new stake in shares of Unicycive Therapeutics during the 4th quarter worth approximately $1,154,000. Finally, Geode Capital Management LLC lifted its position in shares of Unicycive Therapeutics by 36.2% during the 4th quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock worth $989,000 after buying an additional 45,563 shares during the last quarter. Hedge funds and other institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.